-+ 0.00%
-+ 0.00%
-+ 0.00%

Revolution Medicines starts Phase 3 RASolute 303 trial of daraxonrasib in metastatic pancreatic cancer

Reuters·04/02/2026 12:07:50

Please log in to view news